Learn More
Gibco™ Mouse CXCL2 (GRO beta) Recombinant Protein, PeproTech®
Recombinant Protein
Marca: Gibco™ 250-15-100UG
Descripción
Recombinant Murine MIP-2 is a 7.8 kDa protein consisting of 73 amino acids, including the 'ELR' motif common to the CXC chemokine family that binds to CXCR1 or CXCR2. This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis
Produced by activated monocytes and neutrophils and expressed at sites of inflammation. Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. GRO-beta(5-73) shows a highly enhanced hematopoietic activity.
Especificaciones
P10889 | |
protein with no preservative | |
7.8 kDa | |
100 μg | |
RUO | |
C Cmotif chemokine; C x C motif chemokine; CC motif chemokine; CCmotif chemokine; chemokine (C-X-C motif) ligand 2; CINC-2 A; Cinc3; CINC-3; CXC; CXC motif chemokine; C-X-C motif chemokine 2; C-X-C motif chemokine ligand 2; CXCL; CXCL2; Cytokine-induced neutrophil chemoattractant 3; GRO b; gro beta; GRO β; GRO2; GRO2 oncogene; GROb; GRObeta; gro-beta; GRO-beta(5-73); GRO-beta-T; Growth-regulated protein beta; GROβ; Hematopoietic synergistic factor; HSF; Macrophage inflammatory protein 2; macrophage inflammatory protein 2-alpha; melanoma growth stimulatory activity beta; MGSA beta; Mgsa-b; MIP 2 A; MIP 2 alpha; MIP 2 A; Mip2; MIP-2; MIP2 a; MIP2 a; MIP2A; MIP-2 A; MIP2-alpha; SB-251353; Scyb; Scyb2; small inducible cytokine subfamily, member 2 | |
Cxcl2 | |
Unconjugated | |
AVVASELRCQ CLKTLPRVDF KNIQSLSVTP PGPHCAQTEV IATLKGGQKV CLDPEAPLVQ KIIQKILNKG KAN | |
E. coli | |
≥ 98% by SDS-PAGE gel and HPLC analyses. |
ELISA, Functional Assay, Western Blot | |
20310 | |
Mouse CXCL2 (GRO beta) | |
E. coli | |
<1 EU/ μg | |
CXCL2 | |
Determined by its ability to chemoattract total human neutrophils using a concentration range of 1.0-10.0 ng/ml | |
Recombinant | |
-20°C | |
Lyophilized |
Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.